Table 1.
Demographic and clinicopathologic characteristics of patients with the hobnail variant of papillary thyroid carcinoma in the present study and the literature review
| Characteristic | Number of cases (%) | ||
|---|---|---|---|
|
| |||
| Present study (n = 10) | Review of the literature (n = 45) | Total cases (n = 55) | |
| Female:male ratio | 6:4 (1.5:1) | 32:13 (2.5:1) | 38:17 (2.2:1) |
| Mean age (years) (range) | 50.4 (32-68) | 56.9 (21-86) | 55.7 (21-86) |
| Mean tumor size (cm) (range) | 1.63 (0.6-4) | 3.81 (0.5-11) | 3.41 (0.5-11) |
| Multifocality | 3/10 (30%) | 12/28 (43%) | 15/38 (40%) |
| Tumor site | |||
| Right lobe | 6/10 (60%) | 0/14 (0%) | 6/24 (25%) |
| Left lobe | 4/10 (40%) | 0/14 (0%) | 4/24 (17%) |
| Right and left lobe | 0/10 (0%) | 14/14 (100%) | 14/24 (58%) |
| Results of fine needle aspiration cytology | |||
| Atypia of undetermined significance | 0/10 (0%) | 1/18 (5.6%) | 1/28 (3.6%) |
| PTC | 10/10 (100%) | 16/18 (89%) | 26/28 (93%) |
| PTC, tall cell variant | 0/10 (0%) | 1/18 (5.6%) | 1/28 (3.6%) |
| Original histologic diagnosis | |||
| PTC | 0/10 (0%) | 24/45 (53%) | 24/55 (44%) |
| PTC, classic | 2/10 (20%) | 2/45 (4.4%) | 4/55 (7.3%) |
| PTC with hobnail features | 1/10 (10%) | 1/45 (2.2%) | 2/55 (3.6%) |
| PTC, hobnail variant | 7/10 (70%) | 18/45 (40%) | 25/55 (46%) |
| Chief complaint | |||
| Incidental finding | 9/10 (90%) | 3/15 (20%) | 12/25 (48%) |
| Neck mass | 1/10 (10%) | 8/15 (53%) | 9/25 (36%) |
| Cervical lymphadenopathy | 0/10 (0%) | 2/15 (13%) | 2/25 (8.0%) |
| Dyspnea | 0/10 (0%) | 2/15 (13%) | 2/25 (8.0%) |
| Extrathyroidal extension | 7/10 (70%) | 26/44 (59%) | 33/54 (61%) |
| Tracheal invasion | 1/10 (10%) | 5/43 (12%) | 6/53 (11%) |
| Mean mitotic count (/10HPFs) (range) | 0.2 (0-1) | 2.7 (0-9) | 2.1 (0-9) |
| Necrosis | 2/10 (20%) | 3/45 (6.7%) | 5/55 (9.1%) |
| Lymyphovascular invasion | 8/10 (80%) | 27/43 (63%) | 35/53 (66%) |
| Lymph node metastasis | 8/10 (80%) | 26/41 (63%) | 34/51 (67%) |
| Lateral lymph node metastasis | 4/10 (40%) | 14/40 (35%) | 18/50 (36%) |
| Bone metastasis | 0/10 (0%) | 3/42 (7.1%) | 3/52 (5.8%) |
| Lung metastasis | 0/10 (0%) | 9/42 (21%) | 9/52 (17%) |
| AJCC staging | |||
| I | 4/10 (40%) | 13/41 (32%) | 17/51 (33%) |
| II | 0/10 (0%) | 2/41 (4.9%) | 2/51 (3.9%) |
| III | 4/10 (40%) | 9/41 (22%) | 13/51 (25%) |
| IVA | 2/10 (20%) | 8/41 (20%) | 10/51 (20%) |
| IVC | 0/10 (0%) | 9/41 (22%) | 9/51 (18%) |
| Mutational analysis | |||
| BRAF V600E mutation | 8/10 (80%) | 17/24 (71%) | 25/34 (74%) |
| RET/PTC1 rearrangement | NA | 2/10 (20%) | 2/10 (20%) |
| TERT promoter mutation | 0/10 (0%) | NA | 0/10 (0%) |
| ALK fusion | 0/10 (0%) | NA | 0/10 (0%) |
| Regional/local recurrence | 1/10 (10%) | 11/42 (26%) | 12/52 (23%) |
| Outcome | |||
| No evidence of disease | 9/10 (90%) | 24/42 (5.7%) | 33/52 (64%) |
| Alive with disease | 1/10 (10%) | 8/42 (19%) | 9/52 (17%) |
| Died of disease | 0/10 (0%) | 10/42 (24%) | 10/52 (19%) |
PTC, papillary thyroid carcinoma; HPFs, high power fields; NA, not available; AJCC, American Joint Committee on Cancer.